my mid year review of LCTX | LCTX Message Board Posts

Lineage Cell Therapeutics

  LCTX website

LCTX   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  251 of 256  at  6/30/2023 7:27:29 PM  by


my mid year review of LCTX

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Lineage Cell Therapeutics

LCTX (market cap is $0.240B was $0.199B)

Lineage Cell Therapeutics is a leading-edge biotech advancing several technologies, some more innovative than most, with an expectation of applying for FDA approval for at least one with in the next two years. Two of their most advanced treatments are for dry-eye macular degeneration, and repairing or at least improved motor function for accident victims who suffered nerve damage. There's got to be a more concise way of writing that, but that's part of this general portfolio exercise.

Both major treatments meet unmet needs, or needs that are barely met. Biotech is always advancing, so there is competition, but the needs can be so large and varied that there may be more than enough to benefit from several solutions.

I am glad to be invested in a company that may solve unsolved issues that therefore benefit people. I am also aware that I am not a healthcare, medical, or any similar expert. My amateur spirit may be missing big issues, but I hope to be helping and being helped by being associated with positive significant disruptive goods and services.

(Mostly a copy&paste for my biotech investments with the names changed)

One hurdle with biotechs is making sure the treatment is reliable, effective, safe, and commercially viable. Another hurdle with innovative treatments is gaining FDA approval is a reasonable time. Treatments for unmet needs have pressure for early approval. Innovative treatments have pressures encouraging the FDA to be cautious. We may soon see how the technical, political, medical, and societal pressures affect Geron's treatment and Geron's viability and GERN's performance.

DISCLOSURE LTBH by habit, but having to remember that my LCTX/BTX holdings came from AST (2014) which was spun off from GERN (which I’ve held since 1999). I hear patience pays, but it is easy to have doubts after twenty years of waiting.

(I've also collected links to the other discussion boards and my other stocks over on my blog
& from my One Company One Story series on YouTube )

     e-mail to a friend      printer-friendly     add to library      
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Financial Market Data provided by